Javascript must be enabled to continue!
On‐therapy impedance‐pH monitoring can efficiently characterize PPI‐refractory GERD and support treatment escalation
View through CrossRef
AbstractBackgroundOn‐therapy impedance‐pH monitoring is recommended in patients with documented GERD and PPI‐refractory heartburn in order to establish whether the unremitting symptom is reflux‐related or not.AimsTo define on‐PPI cut‐offs of impedance‐pH metrics allowing proper interpretation of on‐therapy impedance‐pH monitoring.MethodsBlinded expert review of impedance‐pH tracings performed during double‐dosage PPI, prospectively collected from 150 GERD patients with PPI‐refractory heartburn and 45 GERD patients with PPI‐responsive heartburn but persisting extra‐esophageal symptoms. Acid exposure time (AET), number of total refluxes (TRs), post‐reflux swallow‐induced peristaltic wave (PSPW) index, and mean nocturnal baseline impedance (MNBI) were assessed. On‐PPI cut‐offs were defined and evaluated with ROC analysis and the area under curve (AUC).ResultsAll the four impedance‐pH metrics significantly differed between PPI‐refractory and PPI‐responsive heartburn cases. At ROC analysis, AUC was 0.73 for AET, 0.75 for TRs, 0.81 for PSPW index, and 0.71 for MNBI; best cut‐offs were ≥1.7% for AET, ≥45 for TRs, ≤36% for PSPW index, and ≤ 1847 Ω for MNBI; AUC of such cut‐offs was 0.66, 0.71, 0.73, and 0.68, respectively. Analysis of PSPW index and MNBI added to assessment of AET and TRs significantly increased the yield of on‐therapy impedance‐pH monitoring in the PPI‐refractory cohort (97% vs. 83%, p < 0.0001). Notably, suboptimal acid suppression as shown by AET ≥1.7% was detected in 43% of 150 PPI‐refractory cases.ConclusionsWe have defined on‐PPI cut‐offs of impedance‐pH metrics by which comprehensive assessment of impedance‐pH tracings, including analysis of PSPW index and MNBI can efficiently characterize PPI‐refractory GERD and support treatment escalation.
Title: On‐therapy impedance‐pH monitoring can efficiently characterize PPI‐refractory GERD and support treatment escalation
Description:
AbstractBackgroundOn‐therapy impedance‐pH monitoring is recommended in patients with documented GERD and PPI‐refractory heartburn in order to establish whether the unremitting symptom is reflux‐related or not.
AimsTo define on‐PPI cut‐offs of impedance‐pH metrics allowing proper interpretation of on‐therapy impedance‐pH monitoring.
MethodsBlinded expert review of impedance‐pH tracings performed during double‐dosage PPI, prospectively collected from 150 GERD patients with PPI‐refractory heartburn and 45 GERD patients with PPI‐responsive heartburn but persisting extra‐esophageal symptoms.
Acid exposure time (AET), number of total refluxes (TRs), post‐reflux swallow‐induced peristaltic wave (PSPW) index, and mean nocturnal baseline impedance (MNBI) were assessed.
On‐PPI cut‐offs were defined and evaluated with ROC analysis and the area under curve (AUC).
ResultsAll the four impedance‐pH metrics significantly differed between PPI‐refractory and PPI‐responsive heartburn cases.
At ROC analysis, AUC was 0.
73 for AET, 0.
75 for TRs, 0.
81 for PSPW index, and 0.
71 for MNBI; best cut‐offs were ≥1.
7% for AET, ≥45 for TRs, ≤36% for PSPW index, and ≤ 1847 Ω for MNBI; AUC of such cut‐offs was 0.
66, 0.
71, 0.
73, and 0.
68, respectively.
Analysis of PSPW index and MNBI added to assessment of AET and TRs significantly increased the yield of on‐therapy impedance‐pH monitoring in the PPI‐refractory cohort (97% vs.
83%, p < 0.
0001).
Notably, suboptimal acid suppression as shown by AET ≥1.
7% was detected in 43% of 150 PPI‐refractory cases.
ConclusionsWe have defined on‐PPI cut‐offs of impedance‐pH metrics by which comprehensive assessment of impedance‐pH tracings, including analysis of PSPW index and MNBI can efficiently characterize PPI‐refractory GERD and support treatment escalation.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
The added diagnostic value of postreflux swallow‐induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on‐therapy impedance‐pH monitoring
The added diagnostic value of postreflux swallow‐induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on‐therapy impedance‐pH monitoring
AbstractBackgroundOn‐therapy impedance‐pH monitoring in proton pump inhibitor (PPI)‐refractory gastroesophageal reflux disease (GERD) yielded conflicting results. We aimed to asses...
Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring
Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring
OBJECTIVES:
Role of reflux and mechanisms of response to proton pump inhibitor (PPI) therapy in eosinophilic esophagitis (EoE) have not yet been fully elucidate...
Applying Lyon Consensus criteria in the work‐up of patients with proton pump inhibitory‐refractory heartburn
Applying Lyon Consensus criteria in the work‐up of patients with proton pump inhibitory‐refractory heartburn
SummaryBackgroundA hierarchical approach for gastro‐oesophageal reflux disease (GERD) diagnosis by impedance‐pH monitoring was proposed by the Lyon Consensus, based on acid exposur...
Editor’s Pick: Refractory Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Management
Editor’s Pick: Refractory Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Management
Gastroesophageal reflux disease (GERD) is one of the most commonly encountered gastrointestinal diseases in clinical practice. Proton pump inhibitors (PPI) remain the cornerstone o...

